We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+21.97%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$2.76B
AUM Growth
+$163M
Cap. Flow
-$58.5M
Cap. Flow %
-2.12%
Top 10 Hldgs %
29.44%
Holding
155
New
9
Increased
52
Reduced
20
Closed
11

Top Buys

Rank Stock Value
1
BSX icon
Boston Scientific
BSX
+$21.9M
2
EHC icon
Encompass Health
EHC
+$17.3M
3
ALLK
Allakos
ALLK
+$16.6M
4
ELAN icon
Elanco Animal Health
ELAN
+$13.2M
5
ENTA icon
Enanta Pharmaceuticals
ENTA
+$9.27M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$26.1M
2
GILD icon
Gilead Sciences
GILD
+$25.9M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$24.1M
4
ACHC icon
Acadia Healthcare
ACHC
+$22.1M
5
NUVA
NuVasive, Inc.
NUVA
+$19.4M

Sector Composition

Rank Sector Weight
1 Healthcare 89.9%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DVAX
126
DELISTED
Dynavax Technologies
DVAX
$3.32M 0.12%
268,000
– –
YARW
127
Yarrow Bioscience, Inc. Common Stock
YARW
$111M
$3.25M 0.12%
92
– –
ARVN icon
128
Arvinas
ARVN
$572M
$2.53M 0.09%
+150,000
New +$2.47M
CHMA
129
DELISTED
Chiasma, Inc. Common Stock
CHMA
$1.89M 0.07%
525,000
– –
MCRB icon
130
Seres Therapeutics
MCRB
$48.9M
$1.67M 0.06%
11,000
– –
CDTX
131
DELISTED
Cidara Therapeutics
CDTX
$1.32M 0.05%
15,000
– –
NVCR icon
132
NovoCure
NVCR
$1.91B
$1.31M 0.05%
+25,000
New +$995K
UROV
133
DELISTED
Urovant Sciences Ltd.
UROV
$1.2M 0.04%
+100,000
New +$1.18M
SCYX icon
134
SCYNEXIS
SCYX
$52M
$984K 0.04%
10,250
– –
ONCT
135
CALL
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
$79K ﹤0.01%
+357
New +$857K
COR icon
136
Cencora
COR
$61.2B
– –
-220,000
Closed -$18.8M
GILD icon
137
Gilead Sciences
GILD
$165B
– –
-365,000
Closed -$25.9M
HOLX
138
DELISTED
Hologic
HOLX
– –
-400,000
Closed -$15.9M
JAZZ icon
139
Jazz Pharmaceuticals
JAZZ
$16.7B
– –
-98,000
Closed -$16.9M
KNSA icon
140
Kiniksa Pharmaceuticals
KNSA
$5.93B
– –
-90,000
Closed -$1.56M
MCK icon
141
McKesson
MCK
$101B
– –
-5,000
Closed -$667K
PRTA icon
142
CALL
Prothena Corp
PRTA
$450M
– –
-85,000
Closed -$1.24M
KA
143
DELISTED
Kineta, Inc. Common Stock
KA
– –
-3,367
Closed -$1.31M
ONCT
144
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
– –
-2,529
Closed -$6.07M
NUVA
145
DELISTED
NuVasive, Inc.
NUVA
– –
-372,500
Closed -$19.4M
EVHC
146
DELISTED
Envision Healthcare Holdings Inc
EVHC
– –
-110,300
Closed -$4.85M
2 3 4 5
6

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q3 2018 Portfolio in Review

As of Q3 2018, Rock Springs Capital Management held 155 positions worth $2.76B, up 6.3% from $2.6B the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Rock Springs Capital Management's Q3 2018 filing shows 9 new, 52 increased, 20 reduced and 11 closed positions. Its largest new stake was Allakos: 405,000 shares worth $18.2M. The largest sale was AbbVie, an estimated $26.1M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 89% a quarter earlier.

  • Rock Springs Capital Management's largest Q3 2018 buy was Allakos: 405,000 shares worth $18.2M.
  • Rock Springs Capital Management added most to Boston Scientific in Q3 2018, an estimated $21.9M increase.
  • Rock Springs Capital Management's biggest Q3 2018 reduction was AbbVie, cutting an estimated $26.1M.
  • Rock Springs Capital Management fully exited Gilead Sciences in Q3 2018, selling an estimated $25.9M.
  • Rock Springs Capital Management's ten largest holdings make up 29% of its $2.76B portfolio in Q3 2018.
  • Rock Springs Capital Management opened 9 new positions and closed 11 in Q3 2018.
  • Rock Springs Capital Management's portfolio value rose 6.3% quarter-over-quarter to $2.76B.

Based on Rock Springs Capital Management's 13F filing for Q3 2018, filed 14 Nov 2018.